Journal article
Towards optimal endocrine therapy for hormone-sensitive breast cancer: Initial versus sequential adjuvant aromatase inhibition
Abstract
Patients with hormone-receptor-positive early breast cancer have a significant risk of recurrence despite the use of adjuvant tamoxifen. The third-generation aromatase inhibitors letrozole, anastrozole, and exemestane offer promise as alternative or additional therapy to tamoxifen. As extended adjuvant therapy following completion of 5 years of tamoxifen, letrozole further decreased the risk of recurrence compared with placebo. Compared with …
Authors
Spicer J; Ellis P
Journal
Cancer Letters, Vol. 248, No. 2, pp. 165–174
Publisher
Elsevier
Publication Date
April 2007
DOI
10.1016/j.canlet.2006.07.002
ISSN
0304-3835